Technical aspects of HLA antibody testing

Current Opinion in Organ Transplantation

Volumn 18, Issue 4, 2013, Pages 455-462

  Gebel, Howard M ^a   Liwski, Robert S ^b   Bray, Robert A ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

donor specific antibodies; HLA antibodies; virtual crossmatching

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; HLA B7 ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; IMMUNOGLOBULIN M ANTIBODY;

ALLELE; ANTIBODY DETECTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; BLOOD GROUP TYPING; CELL ISOLATION; COMPLEMENT FIXATION; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNOASSAY; LIVING DONOR; MAINTENANCE THERAPY; PHENOTYPE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; STANDARDIZATION;

BLOOD GROUPING AND CROSSMATCHING; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84880923920     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32836361f1     Document Type: Review

References (46)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739
2. Delmonico FL, Fuller A, Cosimi AB, et al. New approaches to donor crossmatching and successful transplantation of highly sensitized patients. Transplantation 1983; 36:629-633
3. Gebel HM, Bray RA. The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Neph Hypertens 2010; 19:598-602
4. Gebel HM, Bray RA, Nickerson PW. Pretransplant assessment of donor reactive, HLA specific antibodies in renal transplantation: Contraindication vs risk. Am J Transplant 2003; 3:1488-1500
5. Lin A, Xu H, Yan W. Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol 2007; 4:91-98
6. Kuipers K, Biesta P, Groothuis T, et al. Statins affect cell-surface expression of major histocompatibility complex II molecules by disrupting cholesterol containing microdomains. Hum Immunol 2005; 66:653-665
7. Hetrick SJ, Schillinger KP, Zachary AA, Jackson AM. Impact of pronase on flow cytometric crossmatch outcome. Hum Immunol 2011; 72:330-336
8. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998; 5:313-322
9. Pei R, Lee J-H, Shih N-J, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antibody specificities. Transplantation 2003; 75:43-49
10. Welsh K, Bunce M. Molecular typing for the MHC with PCR-SSP. Rev Immunogenet 1999; 1:157-176
11. Tiercy JM, Jeannet M, Mach B. A new approach for the analysis of HLA class II polymorphism: 'HLA oligotyping'. Blood Rev 1990; 4:9-15
12. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6:2307-2315
13. Appel JZ, Hartwig MG, Cantu E, et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81:1049-1057
14. Zangwill S, Ellis T, Stendahl G, et al. Practical application of the virtual crossmatch. Pediatr Transplant 2007; 11:650-654
15. Ferrari P, Fidler S, Wright J, et al. Virtual crossmatch approach to maximize matching in paired kidney donation. Am J Transplant 2011; 11:272-278
16. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS. Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11:719-724
17. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95:19-47
18. Taylor CJ, Kosmoliaptsis V, Sharples LD, et al. Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation 2010; 89:185-193
19. Tambur AR, Ramon DS, Kaufman DB, et al. Perception versus reality?: Virtual crossmatch -how to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9:1886-1893
20. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12:1618-1623
21. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11:2132-2143
22. Amico P, Hirt-Minkowski P, Hönger G, et al. Risk stratification by the virtual crossmatch: A prospective study in 233 renal transplantations. Transpl Int 2011; 24:560-569
23. Caro-Oleas JL, Gonzá lez-Escribano MF, Gentil-Govantes MÁ, et al. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation 2012; 94:338-344
24. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398-1406
25. Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: A Collaborative Transplant Study report. Transplantation 2011; 91:883-887
26. Zoet YM, Brand-Schaaf SH, Roelen DL, et al. Challenging the golden standard in defining donor-specific antibodies: Does the solid phase assay meet the expectations? Tissue Antigens 2011; 77:225-228
27. Pereira S, Perkins S, Lee JH, et al. Donor-specific antibody against denatured HLA-A1: Clinically nonsignificant? Hum Immunol 2011; 72:492-498
28. Jacob EK, De Goey SR, Gandhi MJ. Positive virtual crossmatch with negative flow crossmatch results in two cases. Transpl Immunol 2011; 25:77-81
29. Poli F, Benazzi E, Innocente A, et al. Heart transplantation with donor-specific antibodies directed toward denatured HLA-A-02:01: A case report. Hum Immunol 2011; 72:1045-1048
30. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10:582-589
31. Zachary A, Reinsmoen NL. Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 2011; 16:410-415
32. Bray RA, Tarsitani C, Gebel HM, Lee JH. Clinical cytometry and progress in HLA antibody detection. Methods Cell Biol 2011; 103:285-310
33. Congy-Jolivet N, Drocourt D, Portet S, et al. Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection. J Immunol Methods 2013; 390:41-51
34. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011; 92:510-515
35. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009; 70:496-501
36. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72:849-858
37. Wahrmann M, Hlavin G, Fischer G, et al. Modified solid-phase alloantibody detection for improved crossmatch prediction.HumImmunol 2013; 74:32-40
38. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibodymediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32:98-105
39. Hönger G, Hopfer H, Arnold ML, et al. Pretransplant IgG subclasses of donorspecific human leukocyte antigen antibodies and development of antibodymediated rejection. Transplantation 2011; 92:41-47
40. Lawrence C, Willicombe M, Brookes PA, et al. Preformed complementactivating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 2013; 95:341-346
41. Ravindranath MH, Kaneku H, El-Awar N, et al. Antibodies to HLA-E in nonalloimmunized males: Pattern of HLA-Ia reactivity of anti-HLA-E positive sera. J Immunol 2010; 185:1935-1948
42. Ellis TM, Schiller JJ, Roza AM, et al. Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength. Hum Immunol 2012; 73:706-710
43. Liwksi R, Adams G, Peladeau G, et al. An optimized flow cytometric crossmatch assay expedites pretransplant immunologic risk assessment. Hum Immunol 2011; 72 (Suppl 1):S48
44. Cai J, Terasaki PI, Anderson N, et al. Intact HLA not beta2m-free heavy chainspecific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88:226-230
45. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73:1269-1273
46. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13:1859-1870